R Erro1,2, M Picillo3, C Vitale4,5, M Amboni5, M Moccia6, G Santangelo7, M T Pellecchia3, P Barone3. 1. Sobell Department of Motor Neuroscience and Movement Disorders, UCL Institute of Neurology, London, UK. erro.roberto@gmail.com. 2. Department of Neuroscience, Biomedicine and Movement Science, University of Verona, Verona, Italy. erro.roberto@gmail.com. 3. Department of Medicine and Surgery, Center for Neurodegenerative diseases (CEMAND), Neuroscience Section, University of Salerno, Baronissi (SA), Italy. 4. University Parthenope, Naples, Italy. 5. IDC-Hermitage-Capodimonte, Naples, Italy. 6. Department of Neuroscience, Reproductive and Odontostomatologic Sciences, University of Naples Federico II, Naples, Italy. 7. Department of Psychology, Second University of Naples, Caserta, Italy.
Abstract
BACKGROUND AND PURPOSE: Very little is known about the progression of non-motor symptoms (NMSs) in Parkinson's disease (PD) and there are no longitudinal studies exploring this topic from the earliest stage, when patients receive the diagnosis. We here report on the progression of NMSs over 4 years from diagnosis in a cohort of de-novo, previously untreated, patients with PD. METHODS: Consecutive de-novo (disease duration < 2 years), untreated patients with PD were enrolled in this observational study. Evaluations were then scheduled every 2 years and included assessment of motor and non-motor features as well as of quality of life measures. RESULTS: Sixty-one patients were prospectively followed-up for 4 years from diagnosis. The majority of NMSs increased over time and significantly affected quality of life, whereas motor disability did not. There was no significant association between NMSs and dopaminergic therapy in terms of both drug class and total levodopa-equivalent daily dosage. Excessive daytime sleepiness was the only NMS correlating with therapy with dopamine agonists. Female patients were more likely to have worse quality of life. CONCLUSIONS: Non-motor symptoms significantly increase over time, with a different progression rate for each one. NMSs significantly affect quality of life in PD and we here demonstrated that this was especially the case when patients were in their (motor) honeymoon period. Future trials should target non-dopaminergic networks and consider NMSs in their outcomes.
BACKGROUND AND PURPOSE: Very little is known about the progression of non-motor symptoms (NMSs) in Parkinson's disease (PD) and there are no longitudinal studies exploring this topic from the earliest stage, when patients receive the diagnosis. We here report on the progression of NMSs over 4 years from diagnosis in a cohort of de-novo, previously untreated, patients with PD. METHODS: Consecutive de-novo (disease duration < 2 years), untreated patients with PD were enrolled in this observational study. Evaluations were then scheduled every 2 years and included assessment of motor and non-motor features as well as of quality of life measures. RESULTS: Sixty-one patients were prospectively followed-up for 4 years from diagnosis. The majority of NMSs increased over time and significantly affected quality of life, whereas motor disability did not. There was no significant association between NMSs and dopaminergic therapy in terms of both drug class and total levodopa-equivalent daily dosage. Excessive daytime sleepiness was the only NMS correlating with therapy with dopamine agonists. Female patients were more likely to have worse quality of life. CONCLUSIONS: Non-motor symptoms significantly increase over time, with a different progression rate for each one. NMSs significantly affect quality of life in PD and we here demonstrated that this was especially the case when patients were in their (motor) honeymoon period. Future trials should target non-dopaminergic networks and consider NMSs in their outcomes.
Authors: Paulo Bugalho; Filipa Ladeira; Raquel Barbosa; João P Marto; Claudia Borbinha; Laurete da Conceição; Manuel Salavisa; Marlene Saraiva; Bruna Meira; Marco Fernandes Journal: Mov Disord Clin Pract Date: 2021-06-19
Authors: Pablo Martinez-Martin; Anette Schrag; Daniel Weintraub; Alexandra Rizos; Carmen Rodriguez-Blazquez; Kallol Ray Chaudhuri Journal: Mov Disord Clin Pract Date: 2019-02-05
Authors: Diego Santos-García; Teresa de Deus; Carlos Cores; Hector Canfield; Jose M Paz González; Cristina Martínez Miró; Lorena Valdés Aymerich; Ester Suárez; Silvia Jesús; Miquel Aguilar; Pau Pastor; Lluis Planellas; Marina Cosgaya; Juan García Caldentey; Nuria Caballol; Ines Legarda; Jorge Hernández-Vara; Iria Cabo; Lydia López Manzanares; Isabel González Aramburu; Maria A Ávila Rivera; Maria J Catalán; Victor Nogueira; Victor Puente; Julio Dotor; Carmen Borrué; Berta Solano; Maria Álvarez Sauco; Lydia Vela; Sonia Escalante; Esther Cubo; Francisco Carrillo; Juan C Martínez Castrillo; Pilar Sánchez Alonso; Gemma Alonso; Nuria López Ariztegui; Itziar Gastón; Jaime Kulisevsky; Marta Blázquez; Manuel Seijo; Javier Rúiz Martínez; Caridad Valero; Monica Kurtis; Oriol de Fábregues; Jessica Ardura; Ruben Alonso; Carlos Ordás; Luis M López Díaz; Darrian McAfee; Pablo Martinez-Martin; Pablo Mir Journal: J Pers Med Date: 2021-06-30